CM
RVMD icon

Caption Management’s Revolution Medicines RVMD Stock Holding History

Caption Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.4M Sell
323,100
-413,000
-56% -$41.7M 0.18% 115
2025
Q4 		$58.6M Buy
736,100
+220,100
+43% +$14.4M 0.4% 53
2025
Q3 		$24.1M Buy
516,000
+220,800
+75% +$8.65M 0.19% 113
2025
Q2 		$10.9M Buy
+295,200
New +$11.3M 0.12% 190
2025
Q1 		– Sell
-87,400
Closed -$3.82M – 1964
2024
Q4 		$3.82M Buy
+87,400
New +$4.41M 0.04% 462
2024
Q2 		– Sell
-15,000
Closed -$483K – 1455
2024
Q1 		$483K Sell
15,000
-35,000
-70% -$1.04M 0.01% 877
2023
Q4 		$1.43M Buy
50,000
+30,600
+158% +$735K 0.02% 711
2023
Q3 		$537K Sell
19,400
-27,500
-59% -$816K 0.01% 919
2023
Q2 		$1.25M Buy
+46,900
New +$1.15M 0.02% 610
2021
Q4 		– Sell
-29,200
Closed -$803K – 1893
2021
Q3 		$803K Buy
+29,200
New +$850K 0.01% 1084

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caption Management's RVMD Position: Q4 2025 in Review

Caption Management sold out of Revolution Medicines (RVMD) in Q4 2025, closing a stake of 314,836 shares — an estimated $20.6M sold.

Caption Management first reported a position in RVMD in Q3 2023 and held it in 4 quarters. The position peaked at $14.7M in Q3 2025. 386 funds tracked by Wall St. Rank hold RVMD as of Q4 2025.

  • Caption Management reported no remaining Revolution Medicines position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 314,836 Revolution Medicines shares in Q4 2025, an estimated $20.6M.
  • Caption Management first reported a position in Revolution Medicines in Q3 2023 and held it in 4 quarters.
  • Caption Management's Revolution Medicines position peaked at $14.7M in Q3 2025.
  • 386 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.